By following a conjugation approach, in 2012, some of us developed a new series of hybrid compounds that integrated the pharmacological activities of two drugs marketed for AD, which are the acetylcholinesterase inhibitor (AChEI) galantamine and the N-methyl-d-aspartate receptor (NMDAR) antagonist memantine [25] (Figure 2). This evidence concerns the gene ACHE and Alzheimer disease.